Aston Pharmaceuticals IPO opening date is July 9, 2025 and the IPO will close on July 11, 2025. Aston Pharmaceuticals IPO is a book build issue. The company will raise approximately ₹27.56 crore through the IPO, comprising fresh shares worth ₹27.56 crore and [.] equity shares with face value of ₹10 are being made available to the public.
Aston Pharmaceuticals IPO price band is estimated to be ₹115 to ₹123 per share. Retail quota is 35%, QIB 50% and HNI 15%. Aston Pharmaceuticals IPO is being listed on BSE on July 16, 2025. Aston Pharmaceuticals IPO allotment date announced on July 14, 2025.
The company has established itself as a good and stable company and has recorded a revenue of ₹25.61 crores in 2025, while it was ₹15.84 crores in 2024. The company has recorded a profit of ₹4.33 crores in 2025, while it was ₹1.36 crores in 2024. As per the financial position, investors in this IPO should invest in the IPO for long term and profit.
Asston Pharmaceuticals IPO Details
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Face Value: | ₹10 Per Equity Share |
| IPO Price Band: | ₹115 to ₹123 Per Share |
| Issue Size: | Approx ₹27.56 Crores |
| Fresh Issue: | Approx ₹27.56 Crores |
| Issue Type: | Book Build Issue |
| IPO Listing: | BSE SME |
| Retail Quota: | Not more than 35% |
| QIB Quota: | Not more than 50% |
| NII Quota: | Not more than 15% |
| DRHP Draft Prospectus: | Click Here |
| RHP Draft Prospectus: | Click Here |
| Anchor Investors List: | Click Here |
Asston Pharmaceuticals IPO Market Lot
The Asston Pharmaceuticals IPO minimum market lot is 2,000 shares with ₹2,46,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 2,000 | ₹2,46,000 |
| Retail Maximum | 2 | 2,000 | ₹2,46,000 |
| S-HNI Minimum | 3 | 3,000 | ₹3,69,000 |
Asston Pharmaceuticals IPO Dates
The Asston Pharmaceuticals IPO date is July 9 and the close date is July 11. The Asston Pharmaceuticals IPO allotment will be finalized on July 14 and the IPO listing on July 16.
| IPO Open Date: | July 9, 2025 |
| IPO Close Date: | July 11, 2025 |
| Basis of Allotment: | July 14, 2025 |
| Refunds: | July 15, 2025 |
| Credit to Demat Account: | July 15, 2025 |
| IPO Listing Date: | July 16, 2025 |
Promoters of Asston Pharmaceuticals IPO
The promoters of the company are Dr. Ashish Narayan Sakalkar, Saili Jayaram More and Sachin Chandrakant Badakh.
About Asston Pharmaceuticals IPO
Established in 2019, Aston Pharmaceuticals Limited is one of the steadily growing companies in the pharmaceutical business and is also involved in the export of healthcare products globally. The company's portfolio includes a wide range of products such as tablets, capsules, sachets, and syrups. The company offers various products across therapeutic categories, including pain relievers, antibiotics, antifungals, vitamins, etc. Aston Pharmaceutical manufactures pharmaceutical products for direct sales and also on contract manufacturing or loan license basis, primarily working in collaboration with various marketers. Aston Pharmaceuticals Limited is certified by both the Central and State FDA, accredited by NQA (Nuclear Quality Assurance), and complies with Quality Management System (QMS) standards, ensuring high-quality manufacturing. The company's portfolio includes several products such as Albendazole USP 400 mg, Diclofenac 100 mg, Ibuprofen, Paracetamol and Ferovit Syrup. As of July 3, 2025, the company has 46 permanent employees and 6 contractual employees.
Asston Pharmaceuticals IPO Company Financial Report
The company reported revenue of ₹25.61 crores in 2025 against ₹15.84 crores in 2024. The company reported profit of ₹4.33 crores in 2025 against profit of ₹1.36 crores in 2024.
Amount ₹ in Crores
| Period Ended | Revenue | Expense | Profit After Tax | Assets |
| 2023 | ₹7.19 | ₹5.78 | ₹1.06 | ₹13.69 |
| 2024 | ₹15.84 | ₹14.02 | ₹1.36 | ₹20.26 |
| 2025 | ₹25.61 | ₹19.91 | ₹4.33 | ₹28.12 |
| May 2025 | ₹6.21 | ₹4.44 | ₹1.32 | ₹31.83 |
Asston Pharmaceuticals IPO Valuation – FY2025
Check Asston Pharmaceuticals IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 50.56% |
| ROCE: | 51.25% |
| EBITDA Margin: | 24.60% |
| PAT Margin: | 17.27% |
| Debt to equity ratio: | 0.68 |
| Earning Per Share (EPS): | ₹6.90 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 40.36% |
| Net Asset Value (NAV): | ₹17.09 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Shelter Pharma Limited | 6.26 | 6.70 | 16.94% | 36.96 | – Cr. |
| Bafna Pharmaceuticals Limited | 1.76 | 51.38 | 4.89% | 35.86 | – Cr. |
| Trident Lifeline Limited | 11.35 | 25.29 | 19.85% | 57.16 | – Cr. |